CLINICAL TRIALS PROFILE FOR PENTOXIL
✉ Email this page to a colleague
All Clinical Trials for PENTOXIL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01625845 ↗ | Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED) | Completed | National Institute of Mental Health (NIMH) | Phase 2 | 2012-06-01 | The objective of this clinical trial is to evaluate whether an anti-inflammatory medication, pentoxifylline, reduces depressive symptoms and improves artery function. Participants in this trial will be older primary care patients (60 years and up) who are depressed but do not have a history of cardiovascular disease. Half of these patients will receive pentoxifylline, and half will receive placebo. In addition, participants in both arms will receive an evidence-based psychological treatment called Beating the Blues®, which is a computerized, cognitive behavioral treatment program for depression. The investigators will use questionnaires to assess change in depressive symptoms and an ultrasound test to measure change in artery function from pre- to post-treatment. It is hypothesized that patients who receive pentoxifylline will show greater improvements in both depression and artery function than patients who receive placebo. |
| NCT01625845 ↗ | Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED) | Completed | Indiana University | Phase 2 | 2012-06-01 | The objective of this clinical trial is to evaluate whether an anti-inflammatory medication, pentoxifylline, reduces depressive symptoms and improves artery function. Participants in this trial will be older primary care patients (60 years and up) who are depressed but do not have a history of cardiovascular disease. Half of these patients will receive pentoxifylline, and half will receive placebo. In addition, participants in both arms will receive an evidence-based psychological treatment called Beating the Blues®, which is a computerized, cognitive behavioral treatment program for depression. The investigators will use questionnaires to assess change in depressive symptoms and an ultrasound test to measure change in artery function from pre- to post-treatment. It is hypothesized that patients who receive pentoxifylline will show greater improvements in both depression and artery function than patients who receive placebo. |
| NCT02487225 ↗ | Pentoxifylline Treatment in Acute Pancreatitis (AP) | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 3 | 2015-05-01 | The purpose of this study was to determine the effects (good and bad) of giving a drug called pentoxifylline to patients with acute pancreatitis. |
| NCT02487225 ↗ | Pentoxifylline Treatment in Acute Pancreatitis (AP) | Completed | Mayo Clinic | Phase 3 | 2015-05-01 | The purpose of this study was to determine the effects (good and bad) of giving a drug called pentoxifylline to patients with acute pancreatitis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PENTOXIL
Condition Name
| Condition Name for PENTOXIL | |
| Intervention | Trials |
| Miscellaneous (i.e. Acute on Chronic Pancreatitis) | 1 |
| Cardiovascular Disease (CVD) | 1 |
| Post-ERCP/Post-procedural Pancreatitis | 1 |
| Coronary Artery Disease (CAD) | 1 |
| [disabled in preview] | 1 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for PENTOXIL
Trials by Country
Clinical Trial Progress for PENTOXIL
Clinical Trial Phase
Clinical Trial Sponsors for PENTOXIL
Sponsor Name
